| Original language | English |
|---|---|
| Pages (from-to) | 1166-1169 |
| Number of pages | 4 |
| Journal | JACC: Cardiovascular Imaging |
| Volume | 15 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Jun 2022 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: JACC: Cardiovascular Imaging, Vol. 15, No. 6, 06.2022, p. 1166-1169.
Research output: Contribution to journal › Letter › Other › peer-review
TY - JOUR
T1 - Phenotypic Features of Coronary Atheroma in Diabetic and Nondiabetic Patients With Low-Density Lipoprotein Cholesterol <55 mg/dL
AU - Iwai, Takamasa
AU - Kataoka, Yu
AU - Nicholls, Stephen J.
AU - Puri, Rishi
AU - Murata, Shunsuke
AU - Nishimura, Kunihiro
AU - Murai, Kota
AU - Kitahara, Satoshi
AU - Sawada, Kenichiro
AU - Matama, Hideo
AU - Honda, Satoshi
AU - Takagi, Kensuke
AU - Fujino, Masashi
AU - Yoneda, Shuichi
AU - Otsuka, Fumiyuki
AU - Nishihira, Kensaku
AU - Asaumi, Yasuhide
AU - Miyamoto, Yoshihiro
AU - Yasuda, Satoshi
AU - Noguchi, Teruo
N1 - Funding Information: The authors declare the following financial interests/personal relationships, which may be considered as potential competing interests: Dr Kataoka has received research support from Nipro and Abbott, and honoraria from Nipro, Abbott, Kowa, Amgen, Sanofi, Astellas, Takeda, and Daiichi-Sankyo. Dr Nicholls is a recipient of a Principal Research Fellowship from the National Health and Medical Research Council of Australia, has received research support from AstraZeneca, Amgen, Anthera, CSL Behring, Cerenis, Eli Lilly, Esperion, Resverlogix, Novartis, InfraReDx, and Sanofi-Regeneron, and is a consultant for Amgen, Akcea, AstraZeneca, Boehringer Ingelheim, CSL Behring, Eli Lilly, Esperion, Kowa, Merck, Takeda, Pfizer, Sanofi-Regeneron, and Novo Nordisk. Dr Puri has received speaker fees from Amgen and Sanofi, served as a consultant for Cerenis, Medtronic, Philips, Boston Scientific, and Shockwave, is on advisory boards for Centerline Biomedical, Medtronic, and Bioventrix, and holds minor equity in Centerline Biomedical. Dr Otsuka is a recipient of a Grant-in-Aid for Scientific Research (C) from the Japan Society for the Promotion of Science (19K08571) and received support and honoraria from Abbott Medical Japan LCC, Amgen Astellas BioPharma KK, Bayer Yakuhin, Boston Scientific Corporation, Bristol-Myers Squibb, Daiichi Sankyo Company, Kowa Pharmaceutical Co, Nipro Corporation, Novartis Pharma KK, Otsuka Pharmaceutical Co, Pfizer Japan, Sanofi KK, Takeda Pharmaceutical Company Limited, and Terumo Corporation. Dr Yasuda has received speaker fees from Bristol-Myers Squibb, Bayer, and Daiichi-Sankyo; and is affiliated with Abbott, Terumo, Nihon-Kohden, Medtronic, Japan Lifeline, Otsuka, Ono, Boehringer Ingelheim, Takeda, Kowa, Zeon, Shionogi, Nippon-Shinyaku, Mochida, and Tesco. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Funding Information: The authors declare the following financial interests/personal relationships, which may be considered as potential competing interests: Dr Kataoka has received research support from Nipro and Abbott, and honoraria from Nipro, Abbott, Kowa, Amgen, Sanofi, Astellas, Takeda, and Daiichi-Sankyo. Dr Nicholls is a recipient of a Principal Research Fellowship from the National Health and Medical Research Council of Australia, has received research support from AstraZeneca, Amgen, Anthera, CSL Behring, Cerenis, Eli Lilly, Esperion, Resverlogix, Novartis, InfraReDx, and Sanofi-Regeneron, and is a consultant for Amgen, Akcea, AstraZeneca, Boehringer Ingelheim, CSL Behring, Eli Lilly, Esperion, Kowa, Merck, Takeda, Pfizer, Sanofi-Regeneron, and Novo Nordisk. Dr Puri has received speaker fees from Amgen and Sanofi, served as a consultant for Cerenis, Medtronic, Philips, Boston Scientific, and Shockwave, is on advisory boards for Centerline Biomedical, Medtronic, and Bioventrix, and holds minor equity in Centerline Biomedical. Dr Otsuka is a recipient of a Grant-in-Aid for Scientific Research (C) from the Japan Society for the Promotion of Science (19K08571) and received support and honoraria from Abbott Medical Japan LCC, Amgen Astellas BioPharma KK, Bayer Yakuhin, Boston Scientific Corporation, Bristol-Myers Squibb, Daiichi Sankyo Company, Kowa Pharmaceutical Co, Nipro Corporation, Novartis Pharma KK, Otsuka Pharmaceutical Co, Pfizer Japan, Sanofi KK, Takeda Pharmaceutical Company Limited, and Terumo Corporation. Dr Yasuda has received speaker fees from Bristol-Myers Squibb, Bayer, and Daiichi-Sankyo; and is affiliated with Abbott, Terumo, Nihon-Kohden, Medtronic, Japan Lifeline, Otsuka, Ono, Boehringer Ingelheim, Takeda, Kowa, Zeon, Shionogi, Nippon-Shinyaku, Mochida, and Tesco. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
PY - 2022/6
Y1 - 2022/6
UR - https://www.scopus.com/pages/publications/85131145447
U2 - 10.1016/j.jcmg.2022.02.005
DO - 10.1016/j.jcmg.2022.02.005
M3 - Letter
C2 - 35680226
AN - SCOPUS:85131145447
SN - 1936-878X
VL - 15
SP - 1166
EP - 1169
JO - JACC: Cardiovascular Imaging
JF - JACC: Cardiovascular Imaging
IS - 6
ER -